Advanced Search

 

Study ID Status Title Patient Level Data
SF2105450 Terminated A randomised, single and repeat dose, double-blind, placebo controlled study to assess the safety and tolerability of GW805858 in healthy volunteers and mild asthmatics
SFA100062 Completed See Detailed Description Study Listed on ClinicalStudyDataRequest.com
SFA100314 Completed A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm Study Listed on ClinicalStudyDataRequest.com
SFA100316 Completed A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm Study Listed on ClinicalStudyDataRequest.com
SFA103081 Terminated An open-label, multi-centre, randomized, parallel group clinical effectiveness study to determine the level of asthma control in adolescent and adult patients with ADVAIR versus usual care for 24 weeks.
SFA103153 Completed A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone Study Listed on ClinicalStudyDataRequest.com
SFA106484 Completed A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma Study Listed on ClinicalStudyDataRequest.com
SFCA3002 Completed A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 100mcg BID Individually and in Combination and Placebo in Subjects with Asthma. Study Listed on ClinicalStudyDataRequest.com
SFCA3003 Completed A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Subjects with Asthma. Study Listed on ClinicalStudyDataRequest.com
SFCA3006 Completed A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulations of salmeterol 50mcg twice daily and fluticasone propionate 500mcg twice daily individually and in combination as compared to placebo in COPD patients. Study Listed on ClinicalStudyDataRequest.com
SFCA3007 Completed A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulation of salmeterol 50mcg twice daily and fluticasone propionate 250mcg twice daily individually and in combination as compared to placebo in COPD patients. Study Listed on ClinicalStudyDataRequest.com
SFCB1001 Completed A study to evaluate the safety, tolerability and systemic pharmacodynamic effects of salmeterol in the salmeterol/FP DISKUS™ inhaler
SFCB1002 Completed A study to evaluate the safety, tolerability, pharmacokinetics and systemic pharmacodynamic effects of fluticasone propionate in the salmeterol/fluticasone propionate DISKUS™ inhaler
SFCB1004 Completed The systemic pharmacodynamic effects and pharmacokinetics of salmeterol and fluticasone propionate when given alone and in combination, after repeat dosing from DISKUS™ inhalers in healthy volunteers
SFCB1005 Completed The systemic pharmacodynamic effects and pharmacokinetics of salmeterol and fluticasone propionate when given together, from either a single or two separate DISKUS™ inhalers, in single doses
SFCB3017 Completed A multicentre randomised, double-blind, double-dummy, parallel group comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) BID via one DISKUS/ACCUHALER inhaler with salmeterol 50mcg BID via one DISKUS/ACCUHALER inhaler and fluticasone propionate 100mcg BID ...
SFCB3018 Completed A multicentre randomised, double-blind, double-dummy, parallel group six-month comparison of the salmeterol/fluticasone propionate combination product (50/250mcg strength) BID via one DISKUS/ACCUHALER inhaler with salmeterol 50mcg BID via one DISKUS/ACCUHALER inhaler and fluticasone propionate 2 ...
SFCB3019 Completed A multicentre randomized, double-blind, double-dummy, parallel-group comparison of the salmeterol/fluticasone propionate combination product (50/500mcg strength) BD via one DISKUS/Accuhaler inhaler with salmeterol 50mcg BD via one DISKUS/Accuhaler and fluticasone propionate 500mcg BD via another ...
SFCB3020 Completed A Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparison of the Salmeterol/Fluticasone Propionate Combination Product (50/100mcg strength) BD Via One DISKUS/ACCUHALER Inhaler with Salmeterol 50mcg BD Via One DISKUS/ACCUHALER and Fluticasone Propionate 100mcg BD Via a Sec ...
SFCB3022 Completed A multicentre, randomised, double-blind, double-dummy, parallel-group, three-month comparison of the salmeterol/fluticasone propionate combination product (2x25/50mcg strength) bd via the pressurised metered dose inhaler with salmeterol/fluticasone propionate combination product (1x50/100mcg str ...
SFCB3023 Completed A multicentre, randomised, double-blind, double-dummy, parallel-group, three-month comparison of the salmeterol/fluticasone propionate combination product (2x25/250mcg strength) bd via the pressurised metered dose inhaler with salmeterol/fluticasone propionate combination product (1x50/500mcg st ...
SFCB3024 Completed A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of the Salmeterol/Fluticasone combination product (50/500mg strength) twice daily with Salmeterol 50mg twice daily alone and Fluticasone Propionate 500mg twice daily alone, all delivered via the Diskus/Accuhaler inhaler, in the treatment of patients with chronic obstructive pulmonary disease. Study Listed on ClinicalStudyDataRequest.com
SFCF4001 Completed Uncontrolled asthma in adults: comparison of combination FP/salmeterol (administered via Diskus) with doubling the dosage of inhaled corticosteroid + long acting ?2-mimetic or adding long acting ?2-mimetic to corticosteroid previously inhaled.
SFCF4002 Completed Asthma controlled by Seretide in adults with persistent moderate asthma : efficacy in preventing exacerbations and quality of life
SFCF4006 Completed Study of control of moderate to severe asthma with Seretide in general practice.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.